Related Experiment Video
Updated: Jul 6, 2026
05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Glycoprotein IIb/IIIa inhibitors
1St George's Hospital, Tooting, London, UK.
Intensive & Critical Care Nursing
|May 15, 2002
Summary
Glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors are effective anti-platelet drugs for acute coronary syndromes and percutaneous coronary intervention (PCI). Careful risk-benefit assessment and cost-effectiveness are crucial for their use.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors are potent anti-platelet agents.
- These agents have demonstrated significant benefits in managing acute coronary syndromes (ACS) and patients undergoing percutaneous coronary intervention (PCI).
Purpose of the Study:
- To evaluate the clinical utility and economic considerations of GPIIb/IIIa inhibitors.
- To highlight the evolving research and clinical experience in this therapeutic area.
Main Methods:
- Review of clinical trial data and pharmacological studies.
- Analysis of risk-benefit profiles and cost-effectiveness in patient populations.
Main Results:
- GPIIb/IIIa inhibitors show proven efficacy in ACS and PCI.
- Individualized assessment of risk versus benefit is essential for optimal patient outcomes.
Conclusions:
- The use of GPIIb/IIIa inhibitors requires careful consideration of individual patient factors and economic impact.
- Ongoing research and growing clinical experience continue to shape the application of these drugs.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:25Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:19Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...